Gilead Sciences (GILD) Declares $0.52 Quarterly Dividend; 2.7% Yield
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/11/2026
- Wall St set to gain on tech rebound, Middle East in focus
- Oracle results beat estimates, but shares fall on plans for $40 billion raise
- Oil prices steady as investors weigh US-Iran war escalation
- Intel rallies as BofA double-upgrades stock on increased CPU, foundry visibility
- Oppenheimer sees little strategic case for Tesla-SpaceX merger
- Needham Starts Hyliion Holdings (HYLN) at Buy
- Oppenheimer Starts SpaceX (SPCX) at Outperform, PT $190, 'space infrastructure appears structurally advantaged'
- Alibaba falls on China AI capex report; Citi says selloff is premature
- Crude Inventory Fell 7.2 Million Barrels Last Week, Says EIA
- Pentagon reportedly locked down, hazmat teams responding
Gilead Sciences (GILD) Tops Q3 EPS by 14c
October 26, 2017 4:04 PM EDTGilead Sciences (NASDAQ: GILD) reported Q3 EPS of $2.27, $0.14 better than the analyst estimate of $2.13. Revenue for the quarter came in at $6.51 billion versus the consensus estimate of $6.39 billion.
For earnings history and earnings-related data on Gilead Sciences (GILD) click here.
... MoreGilead Sciences (GILD) Announces Phase 2 Results for GS-0976 in NASH
October 24, 2017 8:37 AM EDTGilead Sciences, Inc. (Nasdaq: GILD) today announced results from a Phase 2, randomized, placebo-controlled trial evaluating two doses of GS-0976, an oral, investigational inhibitor of Acetyl-CoA carboxylase (ACC), in patients with nonalcoholic steatohepatitis (NASH). The data demonstrate that the higher dose of GS-0976 (20 mg taken orally once daily) when administered for 12 weeks was associated with statistically significant reductions in hepatic steatosis (buildup of fat in the liver) and a noninvasive marker of fibrosis (TIMP-1) compared to placebo. These results are being presented during a late-breaking abstract session at The Liver Meeting® 2017 in... More
